ECSP066461A - Método para activar las poblaciones de célula especificas utilizando conjugados maitansinoides del agente de enlace celular enlazados a través de un enlazador no divisible, dichos conjugados, y métodos para hacer dichos conjugados - Google Patents
Método para activar las poblaciones de célula especificas utilizando conjugados maitansinoides del agente de enlace celular enlazados a través de un enlazador no divisible, dichos conjugados, y métodos para hacer dichos conjugadosInfo
- Publication number
- ECSP066461A ECSP066461A EC2006006461A ECSP066461A ECSP066461A EC SP066461 A ECSP066461 A EC SP066461A EC 2006006461 A EC2006006461 A EC 2006006461A EC SP066461 A ECSP066461 A EC SP066461A EC SP066461 A ECSP066461 A EC SP066461A
- Authority
- EC
- Ecuador
- Prior art keywords
- conjugates
- maitansinoid
- methods
- make
- agent linked
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente invención describe un método para activar maitansinoides para una población de células seleccionada, el método comprende poner en contacto una población de células o tejido que se sospecha que contienen la población de células seleccionadas con un conjugado maitansinoide de agente enlazador de la célula, en donde uno o más maitansinoides están covalentemente enlazados al agente enlazador de la célula a través de un enlazador no divisible y el agente enlazador de la célula se enlaza a las células de la población de célula seleccionada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50990103P | 2003-10-10 | 2003-10-10 | |
US10/960,602 US8088387B2 (en) | 2003-10-10 | 2004-10-08 | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066461A true ECSP066461A (es) | 2007-05-30 |
Family
ID=34467962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006461A ECSP066461A (es) | 2003-10-10 | 2006-03-28 | Método para activar las poblaciones de célula especificas utilizando conjugados maitansinoides del agente de enlace celular enlazados a través de un enlazador no divisible, dichos conjugados, y métodos para hacer dichos conjugados |
Country Status (25)
Country | Link |
---|---|
US (10) | US8088387B2 (es) |
EP (4) | EP1689846B1 (es) |
JP (9) | JP2007520450A (es) |
KR (4) | KR20060130552A (es) |
CN (3) | CN107198778A (es) |
AU (2) | AU2004282491C1 (es) |
BE (1) | BE2013C075I2 (es) |
BR (1) | BRPI0415448A8 (es) |
CA (2) | CA2542128C (es) |
CY (2) | CY1113984T1 (es) |
DK (1) | DK1689846T3 (es) |
EA (1) | EA010508B1 (es) |
EC (1) | ECSP066461A (es) |
ES (1) | ES2404304T3 (es) |
HK (1) | HK1244452A1 (es) |
HR (1) | HRP20130412T1 (es) |
HU (1) | HUS1300075I1 (es) |
IL (4) | IL173625A (es) |
LU (1) | LU92336I2 (es) |
NO (2) | NO337458B1 (es) |
NZ (2) | NZ583844A (es) |
PL (1) | PL1689846T3 (es) |
PT (1) | PT1689846E (es) |
SI (1) | SI1689846T1 (es) |
WO (1) | WO2005037992A2 (es) |
Families Citing this family (290)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2266607A3 (en) | 1999-10-01 | 2011-04-20 | Immunogen, Inc. | Immunoconjugates for treating cancer |
US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
DK2163256T3 (en) | 2001-05-11 | 2015-12-07 | Ludwig Inst For Cancer Res Ltd | Specific binding proteins and use thereof |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
US20110045005A1 (en) * | 2001-10-19 | 2011-02-24 | Craig Crowley | Compositions and methods for the treatment of tumor of hematopoietic origin |
US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
PL210412B1 (pl) * | 2002-05-24 | 2012-01-31 | Schering Corp | Izolowane przeciwciało anty-IGFR lub jego fragment, kompozycja farmaceutyczna, zastosowanie, kwas nukleinowy, zrekombinowany wektor, komórka gospodarza, kompleks, polipeptyd i sposób jego wytwarzania |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) * | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
WO2005082023A2 (en) * | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
CN102973947A (zh) * | 2004-06-01 | 2013-03-20 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
CA2486285C (en) * | 2004-08-30 | 2017-03-07 | Viktor S. Goldmakher | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
US7521541B2 (en) | 2004-09-23 | 2009-04-21 | Genetech Inc. | Cysteine engineered antibodies and conjugates |
EP1817059A2 (en) | 2004-12-01 | 2007-08-15 | Genentech, Inc. | Conjugates of 1,8-bis-naphthalimides with an antibody |
US20110166319A1 (en) * | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
AU2006213662B2 (en) * | 2005-02-11 | 2010-08-05 | Immunogen, Inc. | Process for preparing stable drug conjugates |
JP4875064B2 (ja) * | 2005-04-15 | 2012-02-15 | シェーリング コーポレイション | 癌を処置または予防するための方法および組成物 |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
EP1928503B1 (en) * | 2005-08-24 | 2012-10-03 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
WO2007100385A2 (en) * | 2005-10-31 | 2007-09-07 | Genentech, Inc. | Macrocyclic depsipeptide antibody-drug conjugates and methods |
BRPI0706935A2 (pt) | 2006-01-20 | 2011-04-19 | Genentech Inc | anticorpos anti-efrina b2 isolado, vetor, célula hospedeira, método de elaboração de anticorpo anti-efrina b2, método de elaboração de imunoconjugado anti-efrina b2, método de detecção de efrina b2, método de diagnóstico de disfunção, composição, método de inibição da angiogênese e uso de anticorpo anti-efrina b2 |
AR059851A1 (es) | 2006-03-16 | 2008-04-30 | Genentech Inc | Anticuerpos de la egfl7 y metodos de uso |
MX2008015132A (es) | 2006-05-30 | 2008-12-10 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos. |
LT2845866T (lt) | 2006-10-27 | 2017-07-10 | Genentech, Inc. | Antikūnai ir imunokonjugatai bei jų panaudojimas |
CN104013956B (zh) | 2007-01-25 | 2018-12-18 | 达娜-法勃肿瘤研究所公司 | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 |
MX2009009782A (es) | 2007-03-15 | 2010-09-10 | Ludwig Inst Cancer Res | Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas. |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
CN101679974B (zh) | 2007-03-27 | 2015-09-30 | 航道生物技术有限责任公司 | 包含抗体替代轻链序列的构建体和文库 |
US20090011060A1 (en) * | 2007-07-06 | 2009-01-08 | Peter Koepke | Campsiandra angustifolia extract and methods of extracting and using such extract |
PL2474557T3 (pl) | 2007-07-16 | 2015-02-27 | Genentech Inc | Przeciwciała anty- CD79b i immunokoniugaty i sposoby stosowania |
EP2641618A3 (en) | 2007-07-16 | 2013-10-23 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
EP2188311B1 (en) | 2007-08-14 | 2016-10-05 | Ludwig Institute for Cancer Research Ltd. | Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof |
EP3831380A3 (en) | 2007-08-17 | 2021-12-01 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
US7879369B2 (en) | 2007-09-18 | 2011-02-01 | Selvamedica, Llc | Combretum laurifolium Mart. extract and methods of extracting and using such extract |
TWI640535B (zh) | 2008-01-31 | 2018-11-11 | 建南德克公司 | 抗-cd79b抗體及免疫共軛物及使用方法 |
KR20210131473A (ko) | 2008-03-18 | 2021-11-02 | 제넨테크, 인크. | 항-her2 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법 |
CA2722109A1 (en) * | 2008-04-30 | 2009-11-05 | Immunogen, Inc. | Potent conjugates and hydrophilic linkers |
MY186725A (en) * | 2008-04-30 | 2021-08-13 | Immunogen Inc | Cross-linkers and their uses |
WO2009134870A1 (en) * | 2008-04-30 | 2009-11-05 | Immunogen, Inc. | Potent cell-binding agent drug conjugates |
US20100092495A1 (en) * | 2008-04-30 | 2010-04-15 | Immunogen Inc. | Potent cell-binding agent drug conjugates |
DK2318832T3 (da) | 2008-07-15 | 2014-01-20 | Academia Sinica | Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder |
JP5977522B2 (ja) | 2009-02-05 | 2016-08-24 | イミュノジェン・インコーポレーテッド | 新規ベンゾジアゼピン誘導体 |
HRP20221471T1 (hr) * | 2009-03-25 | 2023-02-03 | Genentech, Inc. | Protutijela anti-fgfr3 i postupci za njihovu uporabu |
EP2414399A1 (en) | 2009-04-01 | 2012-02-08 | F. Hoffmann-La Roche AG | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
AU2010230563A1 (en) | 2009-04-02 | 2011-09-22 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain Fab fragments |
EP2424875B1 (en) | 2009-04-29 | 2016-01-06 | Bio-Rad Laboratories, Inc. | Purification of immunoconjugates |
WO2010126551A1 (en) | 2009-04-30 | 2010-11-04 | Immunogen, Inc. | Potent conjugates and hydrophilic linkers |
EP2430047B1 (en) | 2009-05-13 | 2018-03-28 | i2 Pharmaceuticals, Inc. | Neutralizing molecules to influenza viruses |
PT2437790T (pt) | 2009-06-03 | 2019-06-04 | Immunogen Inc | Métodos de conjugação |
KR20180056805A (ko) | 2009-06-04 | 2018-05-29 | 노파르티스 아게 | IgG 콘쥬게이션을 위한 자리의 확인 방법 |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
IN2012DN03025A (es) * | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
SG10201408401RA (en) | 2009-09-16 | 2015-01-29 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
NZ621655A (en) * | 2009-10-26 | 2015-08-28 | Nestec Sa | Assays for the detection of anti-tnf drugs and autoantibodies |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
JP6184695B2 (ja) | 2009-12-04 | 2017-08-23 | ジェネンテック, インコーポレイテッド | 多重特異性抗体、抗体アナログ、組成物、及び方法 |
US20110165155A1 (en) * | 2009-12-04 | 2011-07-07 | Genentech, Inc. | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 |
DK2516465T3 (en) | 2009-12-23 | 2016-06-06 | Hoffmann La Roche | ANTI-BV8 ANTIBODIES AND APPLICATIONS THEREOF |
JP5841072B2 (ja) | 2010-02-10 | 2016-01-06 | イミュノジェン・インコーポレーテッド | Cd20抗体およびその使用 |
CA2787657A1 (en) * | 2010-02-23 | 2011-09-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
SG10201501342UA (en) | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
CN102971012B (zh) | 2010-03-12 | 2016-05-04 | 伊缪诺金公司 | Cd37结合分子及其免疫缀合物 |
AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
CN102946906B (zh) | 2010-04-23 | 2015-07-15 | 弗·哈夫曼-拉罗切有限公司 | 生产异源多聚体蛋白质 |
CA2795972A1 (en) | 2010-06-03 | 2011-12-08 | Genentech, Inc. | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
SG10201600791TA (en) | 2010-06-08 | 2016-03-30 | Genentech Inc | Cysteine engineered antibodies and conjugates |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
KR101586128B1 (ko) | 2010-08-24 | 2016-01-15 | 에프. 호프만-라 로슈 아게 | 디술피드 안정화 ― Fv 단편을 포함하는 이중특이적 항체 |
AU2011320314B2 (en) | 2010-10-29 | 2015-08-06 | Immunogen, Inc. | Novel EGFR-binding molecules and immunoconjugates thereof |
AU2011320318B9 (en) * | 2010-10-29 | 2015-11-19 | Immunogen, Inc. | Non-antagonistic EGFR-binding molecules and immunoconjugates thereof |
JP5889912B2 (ja) * | 2010-11-17 | 2016-03-22 | ジェネンテック, インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
AU2012211014A1 (en) | 2011-01-24 | 2013-05-02 | National Research Council Of Canada | Antibodies selective for cells presenting EGFR at high density |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
RU2013140685A (ru) | 2011-02-04 | 2015-03-10 | Дженентек, Инк. | ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
SG10201601046QA (en) | 2011-02-15 | 2016-03-30 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
SG193997A1 (en) | 2011-03-29 | 2013-11-29 | Immunogen Inc | Process for manufacturing conjugates of improved homogeneity |
TR201902180T4 (tr) | 2011-03-29 | 2019-03-21 | Immunogen Inc | Tek adimli bi̇r i̇şlem i̇le maytansi̇noi̇d anti̇kor konjugatlarinin hazirlanmasi |
EP2691117A2 (en) * | 2011-03-29 | 2014-02-05 | Immunogen, Inc. | Process for manufacturing conjugates of improved homogeneity |
KR20230013283A (ko) | 2011-04-01 | 2023-01-26 | 이뮤노젠 아이엔씨 | Folr1 암 치료의 효능을 증가시키기 위한 방법 |
JP6018622B2 (ja) | 2011-04-01 | 2016-11-02 | イミュノジェン, インコーポレイテッド | Cd37結合性分子及びその免疫複合体 |
CA2835203A1 (en) | 2011-05-09 | 2012-11-15 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
CN106432506A (zh) | 2011-05-24 | 2017-02-22 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2012171020A1 (en) | 2011-06-10 | 2012-12-13 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
MX350954B (es) | 2011-06-21 | 2017-09-26 | Immunogen Inc | Derivados de maitansinoides novedosos con enlazador de peptido y conjugados de estos. |
WO2013016714A1 (en) | 2011-07-28 | 2013-01-31 | Sea Lane Biotechnologies | Sur-binding proteins against erbb3 |
PE20141151A1 (es) | 2011-09-22 | 2014-09-25 | Amgen Inc | Proteinas de union al antigeno cd27l |
US9364551B2 (en) | 2011-09-29 | 2016-06-14 | Virginia Commonwealth University | Light-enabled drug delivery |
IN2014CN03062A (es) | 2011-10-28 | 2015-07-31 | Hoffmann La Roche | |
CN104168922A (zh) | 2011-11-16 | 2014-11-26 | 安姆根有限公司 | 治疗表皮生长因子缺失突变体viii相关疾病的方法 |
KR20140105765A (ko) | 2011-11-21 | 2014-09-02 | 이뮤노젠 아이엔씨 | EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법 |
MX358680B (es) | 2011-12-08 | 2018-08-31 | Biotest Ag | Usos de inmunoconjugados dirigidos a cd138. |
CA2859744A1 (en) | 2011-12-22 | 2013-06-27 | Sea Lane Biotechnologies, Llc | Surrogate binding proteins |
CA2858806A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2013109994A1 (en) | 2012-01-20 | 2013-07-25 | Sea Lane Biotechnologies, Llc | Surrobody cojugates |
CN104105711B (zh) | 2012-02-10 | 2018-11-30 | 弗·哈夫曼-拉罗切有限公司 | 单链抗体及其他异多聚体 |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
US9764041B2 (en) | 2012-04-04 | 2017-09-19 | Perseus Proteomics Inc. | Drug conjugate comprising anti-CDH3 (P-cadherin) antibody |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
EP2841093A4 (en) | 2012-04-27 | 2016-04-06 | Cytomx Therapeutics Inc | ACTIVATABLE ANTIBODIES FOR BINDING THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR AND USE THEREOF |
KR20150006000A (ko) | 2012-05-01 | 2015-01-15 | 제넨테크, 인크. | 항-pmel17 항체 및 면역접합체 |
WO2013173392A1 (en) | 2012-05-15 | 2013-11-21 | Concortis Biosystems, Corp | Drug-conjugates, conjugation methods, and uses thereof |
US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
NZ630870A (en) | 2012-05-15 | 2016-10-28 | Seattle Genetics Inc | Self-stabilizing linker conjugates |
SG11201407561UA (en) | 2012-05-21 | 2014-12-30 | Genentech Inc | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE |
MX354862B (es) | 2012-06-27 | 2018-03-23 | Hoffmann La Roche | Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes. |
CN104411718B (zh) | 2012-06-27 | 2018-04-24 | 弗·哈夫曼-拉罗切有限公司 | 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途 |
CN104797270A (zh) | 2012-08-02 | 2015-07-22 | 基因泰克公司 | 抗etbr抗体和免疫偶联物 |
CN104717979A (zh) | 2012-08-02 | 2015-06-17 | 基因泰克公司 | 抗etbr抗体和免疫偶联物 |
WO2014031498A1 (en) | 2012-08-18 | 2014-02-27 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
RS58493B1 (sr) | 2012-09-26 | 2019-04-30 | Immunogen Inc | Poboljšani postupak za acilaciju majtanzinola |
WO2014055877A1 (en) | 2012-10-04 | 2014-04-10 | Immunogen, Inc. | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
AU2013344778B2 (en) | 2012-11-15 | 2018-03-22 | Endocyte, Inc. | Conjugates for treating diseases caused by PSMA expressing cells |
JP6133431B2 (ja) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
CN103333246B (zh) * | 2012-12-21 | 2015-09-16 | 百奥泰生物科技(广州)有限公司 | 一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途 |
CN103333179B (zh) * | 2012-12-21 | 2017-06-16 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
EP2961434A2 (en) | 2013-02-28 | 2016-01-06 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US9901647B2 (en) | 2013-02-28 | 2018-02-27 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
US9415118B2 (en) * | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
KR20150127199A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | 항-b7-h4 항체 및 면역접합체 |
WO2014140300A1 (en) | 2013-03-15 | 2014-09-18 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
CN105188766B (zh) | 2013-03-15 | 2019-07-12 | 瑞泽恩制药公司 | 生物活性分子、其偶联物及治疗用途 |
CN105007950B (zh) | 2013-03-15 | 2019-01-15 | 诺华股份有限公司 | 抗体药物缀合物 |
US10233249B2 (en) | 2013-03-19 | 2019-03-19 | Beijing Shenogen Pharma Group Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
CA2910945A1 (en) | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
GB201309807D0 (en) | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
BR112015030514A2 (pt) * | 2013-06-04 | 2017-08-29 | Cytomx Therapeutics Inc | Composições e métodos para conjugação de anticorpos ativáveis |
CN110251683A (zh) | 2013-06-24 | 2019-09-20 | Abl生物公司 | 具有改进的稳定性的抗体-药物缀合物及其用途 |
WO2014210397A1 (en) | 2013-06-26 | 2014-12-31 | Academia Sinica | Rm2 antigens and use thereof |
EP3013347B1 (en) | 2013-06-27 | 2019-12-11 | Academia Sinica | Glycan conjugates and use thereof |
AU2014286872B2 (en) | 2013-07-05 | 2020-01-23 | Formation Biologics Inc. | EGFR antibody conjugates |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
RU2560699C2 (ru) * | 2013-08-02 | 2015-08-20 | федеральное государственное автономное образовательное учреждение высшего профессионального образования "Национальный исследовательский ядерный университет МИФИ" (НИЯУ МИФИ) | Способ создания наноразмерной диагностической метки на основе конъюгатов наночастиц и однодоменных антител |
US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
SG11201601230RA (en) | 2013-08-26 | 2016-03-30 | Regeneron Pharma | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
EP3296408A1 (en) | 2013-09-05 | 2018-03-21 | The Jackson Laboratory | Compositions for rna-chromatin interaction analysis and uses thereof |
JP6486368B2 (ja) | 2013-09-06 | 2019-03-20 | アカデミア シニカAcademia Sinica | 改変されたグリコシル基を含む糖脂質を用いたヒトiNKT細胞の活性化 |
CA2922889A1 (en) | 2013-09-17 | 2015-03-26 | Genentech, Inc. | Methods of using anti-lgr5 antibodies |
RU2696579C2 (ru) | 2013-10-08 | 2019-08-05 | Иммьюноджен, Инк. | Схемы применения иммуноконъюгата анти-folr1 |
ES2754397T3 (es) | 2013-10-11 | 2020-04-17 | Asana Biosciences Llc | Conjugados de proteína-polímero-fármaco |
CA2926586C (en) | 2013-10-11 | 2020-04-07 | Mersana Therapeutics, Inc. | Polymeric scaffold based on phf for targeted drug delivery |
US11103593B2 (en) | 2013-10-15 | 2021-08-31 | Seagen Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
US10836821B2 (en) | 2013-10-15 | 2020-11-17 | Sorrento Therapeutics, Inc. | Drug-conjugates with a targeting molecule and two different drugs |
EA037778B1 (ru) | 2013-10-18 | 2021-05-20 | Дойчес Кребсфоршунгсцентрум | Меченые ингибиторы простатического специфического мембранного антигена (псма), их применение в качестве агентов для визуализации и фармацевтических агентов для лечения рака предстательной железы |
RU2016118573A (ru) | 2013-10-21 | 2017-11-28 | Дженентек, Инк. | Анти-ly6e антитела и способы применения |
US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
EP3068892A4 (en) | 2013-11-13 | 2017-05-31 | Zymeworks Inc. | Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof |
WO2015077891A1 (en) | 2013-11-27 | 2015-06-04 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting her2 |
WO2015089283A1 (en) | 2013-12-11 | 2015-06-18 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
TWI541022B (zh) | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法 |
TWI777502B (zh) | 2013-12-19 | 2022-09-11 | 美商西雅圖遺傳學公司 | 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物 |
US9943606B2 (en) | 2014-01-15 | 2018-04-17 | Rutgers, The State University Of New Jersey | Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents |
WO2015108203A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社オーダーメードメディカルリサーチ | 抗slc6a6抗体を用いたがん治療用医薬組成物 |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
CA2937123A1 (en) | 2014-01-16 | 2015-07-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
BR112016016490B1 (pt) | 2014-01-27 | 2022-11-29 | Pfizer Inc | Compostos de agentes citotóxicos bifuncionais, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos |
KR20160111964A (ko) | 2014-01-29 | 2016-09-27 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 리간드-세포독성 약물 접합체, 이의 제조방법 및 이의 용도 |
KR102532137B1 (ko) | 2014-02-11 | 2023-05-12 | 씨젠 인크. | 단백질의 선택적 환원 |
ES2960619T3 (es) | 2014-02-28 | 2024-03-05 | Hangzhou Dac Biotech Co Ltd | Enlazadores cargados y sus usos para la conjugación |
WO2015148915A1 (en) | 2014-03-27 | 2015-10-01 | Academia Sinica | Reactive labelling compounds and uses thereof |
RU2727012C2 (ru) | 2014-05-06 | 2020-07-17 | Дженентек, Инк. | Получение гетеромультимерных белков с использованием клеток млекопитающих |
JP6894239B2 (ja) | 2014-05-27 | 2021-06-30 | アカデミア シニカAcademia Sinica | 増強された抗体の有効性のための普遍的グリコフォームに関する組成物および方法 |
US10005847B2 (en) | 2014-05-27 | 2018-06-26 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
JP2017518989A (ja) | 2014-05-27 | 2017-07-13 | アカデミア シニカAcademia Sinica | 抗cd20糖操作抗体群およびその使用 |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
US11332523B2 (en) | 2014-05-28 | 2022-05-17 | Academia Sinica | Anti-TNF-alpha glycoantibodies and uses thereof |
RU2695220C2 (ru) * | 2014-06-30 | 2019-07-22 | Тарведа Терапьютикс, Инк. | Нацеленные конъюгаты и частицы и их составы |
DK3160513T3 (da) | 2014-06-30 | 2020-04-06 | Glykos Finland Oy | Saccharidderivat af en toksisk payload og antistofkonjugater deraf |
EP3164420A4 (en) * | 2014-06-30 | 2018-05-23 | Tarveda Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
WO2016008112A1 (en) | 2014-07-16 | 2016-01-21 | Medshine Discovery Inc. | Linkers and application towards adc thereof |
WO2016024195A1 (en) | 2014-08-12 | 2016-02-18 | Novartis Ag | Anti-cdh6 antibody drug conjugates |
KR20240011258A (ko) | 2014-09-02 | 2024-01-25 | 이뮤노젠 아이엔씨 | 항체 약물 컨쥬게이트 조성물의 제형화 방법 |
WO2016036804A1 (en) | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
JP6606545B2 (ja) | 2014-09-03 | 2019-11-13 | イミュノジェン・インコーポレーテッド | 細胞障害性ベンゾジアゼピン誘導体 |
WO2016040369A2 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS |
CN113827737A (zh) | 2014-09-11 | 2021-12-24 | 西雅图基因公司 | 含叔胺药物物质的靶向递送 |
JP2017531620A (ja) | 2014-09-12 | 2017-10-26 | ジェネンテック, インコーポレイテッド | システイン操作抗体及びコンジュゲート |
AR101848A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos de anti-b7-h4 e inmunoconjugados |
DK3262071T3 (da) | 2014-09-23 | 2020-06-15 | Hoffmann La Roche | Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater |
JP2017534612A (ja) | 2014-10-14 | 2017-11-24 | ポリセリックス・リミテッド | Pegの部分を含めた脱離基を含む試薬を用いるペプチド又はタンパク質のコンジュゲーションのための方法 |
CN108064244B (zh) | 2014-11-14 | 2021-09-17 | 诺华股份有限公司 | 抗体药物缀合物 |
JP6721590B2 (ja) | 2014-12-03 | 2020-07-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性抗体 |
WO2016090157A1 (en) | 2014-12-04 | 2016-06-09 | Celgene Corporation | Biomolecule conjugates |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10342858B2 (en) | 2015-01-24 | 2019-07-09 | Academia Sinica | Glycan conjugates and methods of use thereof |
CN107849090A (zh) | 2015-01-28 | 2018-03-27 | 索伦托医疗有限公司 | 抗体药物偶联物 |
US10870706B2 (en) | 2015-03-20 | 2020-12-22 | Pfizer Inc. | Bifunctional cytotoxic agents containing the CTI pharmacophore |
EP3286227A2 (en) | 2015-04-24 | 2018-02-28 | F. Hoffmann-La Roche AG | Multispecific antigen-binding proteins |
TW201711702A (zh) | 2015-06-04 | 2017-04-01 | 應克隆公司 | 使用針對纖維母細胞生長因子受體3(fgfr3)之化合物的療法 |
MA44391A (fr) | 2015-06-08 | 2019-01-23 | Debiopharm Int Sa | Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20 |
EP3308801A4 (en) * | 2015-06-09 | 2019-02-27 | XDCExplorer (Shanghai) Co., Ltd. | ANTIBODY-MEDICINAL CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
EP3310813A1 (en) | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
PT3313845T (pt) | 2015-06-29 | 2020-11-19 | Immunogen Inc | Conjugados de anticorpos de engenharia de cisteína |
WO2017003940A1 (en) * | 2015-06-30 | 2017-01-05 | Tarveda Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
CN113350518A (zh) | 2015-07-12 | 2021-09-07 | 杭州多禧生物科技有限公司 | 与细胞结合分子的共轭偶联的桥连接体 |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
DK3325483T3 (da) | 2015-07-21 | 2020-01-20 | Immunogen Inc | Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater |
WO2017025458A1 (en) | 2015-08-07 | 2017-02-16 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
JP6890581B2 (ja) | 2015-08-28 | 2021-06-18 | デビオファーム インターナショナル, エス. アー. | Cd37の検出のための抗体およびアッセイ |
EP3347049A4 (en) * | 2015-09-08 | 2019-01-30 | Waters Technologies Corporation | MULTIDIMENSIONAL CHROMATOGRAPHY METHOD FOR THE ANALYSIS OF ANTIBODY-ACTIVE CONJUGATES |
RU2749865C2 (ru) | 2015-09-17 | 2021-06-17 | Иммьюноджен, Инк. | Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты |
RU2018116846A (ru) | 2015-10-08 | 2019-11-08 | Займворкс Инк. | Антигенсвязывающие полипептидные конструкции, содержащие легкие цепи каппа и лямбда, и их применения |
CN108473538B (zh) | 2015-10-28 | 2022-01-28 | 塔弗达治疗有限公司 | Sstr靶向缀合物及其颗粒和制剂 |
FI3380525T3 (fi) | 2015-11-25 | 2024-01-30 | Immunogen Inc | Lääkeformulaatioita ja niiden käyttömenetelmiä |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
JP2019501131A (ja) | 2015-12-04 | 2019-01-17 | シアトル ジェネティックス, インコーポレイテッド | 四級化チューブリシン化合物の複合体 |
US9950076B2 (en) | 2016-01-25 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
CA3013412C (en) | 2016-02-04 | 2023-10-10 | Suzhou M-Conj Biotech Co., Ltd. | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof |
AU2017213826A1 (en) | 2016-02-04 | 2018-08-23 | Curis, Inc. | Mutant smoothened and methods of using the same |
WO2017147240A1 (en) | 2016-02-23 | 2017-08-31 | Tarveda Therapeutics, Inc. | Hsp90 targeted conjugates and particles and formulations thereof |
WO2017156192A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
AU2017237186A1 (en) | 2016-03-25 | 2018-11-01 | Seagen Inc. | Process for the preparation of PEGylated drug-linkers and intermediates thereof |
US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
JP7011764B2 (ja) | 2016-07-07 | 2022-01-27 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗体アジュバント複合体 |
KR20240010534A (ko) | 2016-08-09 | 2024-01-23 | 씨젠 인크. | 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체 |
US9950070B2 (en) * | 2016-08-16 | 2018-04-24 | Korea University Research And Business Foundation | HER2 aptamer-anticancer drug complex for cancer cell chemotherapy |
US10538592B2 (en) | 2016-08-22 | 2020-01-21 | Cho Pharma, Inc. | Antibodies, binding fragments, and methods of use |
CN109843334A (zh) | 2016-10-18 | 2019-06-04 | 西雅图基因公司 | 烟酰胺腺嘌呤二核苷酸补救途径抑制剂的靶向递送 |
WO2018075692A2 (en) | 2016-10-19 | 2018-04-26 | Invenra Inc. | Antibody constructs |
JP2020510608A (ja) | 2016-11-02 | 2020-04-09 | デビオファーム インターナショナル, エス. アー. | 抗cd37イムノコンジュゲート療法を改善するための方法 |
EP3538080A4 (en) | 2016-11-14 | 2020-07-08 | Hangzhou Dac Biotech Co., Ltd. | CONJUGATION LINERS, MEDICAMENT-MOLECULE CONJUGATES TO A CELL CONTAINING THE SAME, METHODS OF PREPARING AND USING SUCH CONJUGATES WITH THE BINDERS |
CA3044391A1 (en) | 2016-11-23 | 2018-05-31 | Immunogen, Inc. | Selective sulfonation of benzodiazepine derivatives |
CN110382534B (zh) | 2016-11-29 | 2023-05-09 | 里珍纳龙药品有限公司 | 治疗prlr阳性乳腺癌的方法 |
JP7244987B2 (ja) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
CN110291107B (zh) | 2016-12-22 | 2023-05-05 | 卡坦扎罗麦格纳格拉西亚大学 | 靶向cd43的独特唾液酸糖基化的癌症相关表位的单克隆抗体 |
EP3558391B1 (en) | 2016-12-23 | 2022-02-02 | Immunogen, Inc. | Immunoconjugates targeting adam9 and methods of use thereof |
WO2018129029A1 (en) | 2017-01-04 | 2018-07-12 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
TWI781145B (zh) | 2017-02-28 | 2022-10-21 | 美商伊繆諾金公司 | 具有自分解肽連接子之類美登素衍生物及其結合物 |
US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
US20180346488A1 (en) | 2017-04-20 | 2018-12-06 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
US20180311375A1 (en) * | 2017-04-27 | 2018-11-01 | Cadila Healthcare Limited | Process of preparing antibody-drug conjugate |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
KR20190141181A (ko) | 2017-04-27 | 2019-12-23 | 시애틀 지네틱스, 인크. | 사차화된 니코틴아미드 아데닌 다이뉴클레오타이드 구제 경로 억제제 콘쥬게이트 |
US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
MX2020002241A (es) | 2017-08-28 | 2020-09-03 | Angiex Inc | Anticuerpos anti-tm4sf y métodos de uso de los mismos. |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
US11793885B2 (en) | 2017-12-28 | 2023-10-24 | Immunogen, Inc. | Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders |
WO2019150985A1 (ja) * | 2018-01-31 | 2019-08-08 | 国立大学法人東京大学 | 抗体薬物複合体及びそれを含む医薬組成物 |
PE20201503A1 (es) | 2018-04-13 | 2020-12-29 | Genentech Inc | Formulaciones de inmunoconjugado anti-cd79b estables |
JP2021527047A (ja) | 2018-06-05 | 2021-10-11 | キングス・カレッジ・ロンドン | 消化管系へのペイロード送達のための、btnl3/8を標的とする構築物 |
CA3104511A1 (en) | 2018-06-26 | 2020-01-02 | Immunogen, Inc. | Immunoconjugates targeting adam9 and methods of use thereof |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
KR20210038904A (ko) | 2018-07-25 | 2021-04-08 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘쥬게이트의 효과적인 제조 방법 |
MX2021003382A (es) | 2018-09-26 | 2021-05-27 | Jiangsu Hengrui Medicine Co | Conjugado de ligando y farmaco analogo de exatecan, metodo de preparacion del mismo y aplicacion del mismo. |
TW202029980A (zh) | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途 |
AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
JP2022528020A (ja) | 2019-03-19 | 2022-06-07 | フンダシオ プリバダ インスティトゥト ディンベスティガシオ オンコロジカ デ バル エブロン | 癌の治療のための併用療法 |
WO2020191342A1 (en) | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
EP3947395A1 (en) | 2019-03-29 | 2022-02-09 | ImmunoGen, Inc. | Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases |
US20230135930A1 (en) | 2019-04-24 | 2023-05-04 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
DK3958977T3 (en) | 2019-04-26 | 2023-12-11 | Immunogen Inc | Camptothecinderivater |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
MX2022000450A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 3 Inc | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos. |
US11634508B2 (en) | 2019-07-10 | 2023-04-25 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
CN112125915A (zh) | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
EP4036149A4 (en) | 2019-09-26 | 2023-10-25 | NOF Corporation | HETEROBIFUNCTIONAL MONODISPERSPERED POLYETHYLENE GLYCOL WITH PEPTIDE LINKER |
WO2021136223A1 (en) | 2019-12-31 | 2021-07-08 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
CN115322794A (zh) | 2020-01-11 | 2022-11-11 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
CN114845739A (zh) | 2020-01-22 | 2022-08-02 | 上海森辉医药有限公司 | 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用 |
CN115551552A (zh) | 2020-02-25 | 2022-12-30 | 祐方有限公司 | 喜树碱衍生物及其缀合物 |
CN111195353B (zh) * | 2020-03-19 | 2023-06-23 | 烟台迈百瑞国际生物医药股份有限公司 | 一种美登素类抗体药物偶联物及其应用 |
CN115103858A (zh) | 2020-03-25 | 2022-09-23 | 江苏恒瑞医药股份有限公司 | 一种抗体药物偶联物的制备方法 |
KR20220157998A (ko) | 2020-03-25 | 2022-11-29 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항체 약물 접합체를 포함하는 약학적 조성물 및 이의 용도 |
EP4132588A1 (en) | 2020-04-10 | 2023-02-15 | Seagen Inc. | Charge variant linkers |
US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
WO2022010797A2 (en) | 2020-07-07 | 2022-01-13 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
US20220378929A1 (en) | 2021-02-25 | 2022-12-01 | MediBoston Limted | Anti-her2 antibody-drug conjugates and uses thereof |
CN117279664A (zh) | 2021-04-10 | 2023-12-22 | 普方生物制药美国公司 | Folr1结合剂、其偶联物及其使用方法 |
CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
WO2023092099A1 (en) | 2021-11-19 | 2023-05-25 | Ardeagen Corporation | Gpc3 binding agents, conjugates thereof and methods of using the same |
WO2023169896A1 (en) | 2022-03-09 | 2023-09-14 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
WO2023170216A1 (en) | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
US20240108744A1 (en) | 2022-07-27 | 2024-04-04 | Mediboston Limited | Auristatin derivatives and conjugates thereof |
Family Cites Families (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
GB1603640A (en) | 1977-07-20 | 1981-11-25 | Gist Brocades Nv | Enzyme particles |
US4137230A (en) * | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4265814A (en) * | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) * | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) * | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) * | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) * | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55164687A (en) * | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) * | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) * | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) * | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) * | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) * | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) * | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) * | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) * | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
WO1982001188A1 (en) * | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) * | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4313946A (en) * | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4315929A (en) * | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
JPS57192389A (en) * | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
JPS58167592A (ja) | 1982-03-26 | 1983-10-03 | Takeda Chem Ind Ltd | 新規メイタンシノイド化合物 |
LU86212A1 (fr) | 1985-12-16 | 1987-07-24 | Omnichem Sa | Nouveaux conjugues de la vinblastine et de ses derives,procede pour leur preparation et compositions pharmaceutiques les contenant |
US7838216B1 (en) | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
US5395924A (en) | 1986-03-20 | 1995-03-07 | Dana-Farber Cancer Institute, Inc. | Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US4981979A (en) | 1987-09-10 | 1991-01-01 | Neorx Corporation | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
JPS6484959A (en) | 1987-09-25 | 1989-03-30 | Nec Corp | System for connecting test line |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
US5217713A (en) | 1988-12-27 | 1993-06-08 | Takeda Chemical Industries, Ltd. | Cytotoxic bispecific monoclonal antibody, its production and use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5705157A (en) | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US5154924A (en) | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
FR2656555B1 (fr) * | 1989-12-29 | 1994-10-28 | Serimer | Systeme mecanique de guidage automatique d'une ou plusieurs torches d'une unite de soudage a l'arc. |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
SE9102074D0 (sv) | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
EP0656367A1 (en) | 1991-08-22 | 1995-06-07 | Becton, Dickinson and Company | Method and composition for cancer therapy and for prognosticating responses to cancer theraphy |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
US6022541A (en) | 1991-10-18 | 2000-02-08 | Beth Israel Deaconess Medical Center | Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel |
ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
US7754211B2 (en) * | 1992-04-10 | 2010-07-13 | Research Development Foundation | Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens |
JP2861631B2 (ja) | 1992-05-06 | 1999-02-24 | 日本電気株式会社 | Fsk受信機 |
US6217869B1 (en) | 1992-06-09 | 2001-04-17 | Neorx Corporation | Pretargeting methods and compounds |
CA2120745A1 (en) | 1992-06-30 | 1994-01-06 | Philip G. Kasprzyk | A combination of anti-erbb-2 monoclonal antibodies and method of using |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
WO1994022478A1 (en) | 1993-03-30 | 1994-10-13 | The Trustees Of The University Of Pennsylvania | PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU) |
US6680424B2 (en) | 1994-11-21 | 2004-01-20 | University Of Leeds | Modified proteinase inhibitors |
US5679648A (en) | 1994-11-30 | 1997-10-21 | The University Hospital | Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides |
US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
EP0873363B1 (en) | 1995-06-14 | 2010-10-06 | The Regents of The University of California | High affinity human antibodies to tumor antigens |
US5614692A (en) | 1995-06-30 | 1997-03-25 | Tracor Aerospace, Inc. | Shaped-charge device with progressive inward collapsing jet |
RU2497500C2 (ru) | 1995-07-27 | 2013-11-10 | Джинентех, Инк | Стабильная изотоническая лиофилизированная протеиновая композиция |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US5919815A (en) | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
AU727283B2 (en) | 1996-05-23 | 2000-12-07 | Enzo Nutraceuticals Limited | Process for extraction of proanthocyanidins from botanical material |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
EP0957912A1 (en) | 1996-08-30 | 1999-11-24 | Eli Lilly And Company | Pharmaceutical compounds |
JPH1084959A (ja) * | 1996-09-06 | 1998-04-07 | Nobuyoshi Shimizu | 細胞表面レセプターに対するモノクローナル抗体ならびにそのフラグメントの結合体ならびに複合体、それらの製法ならびに細胞への嵌入方法および使用方法 |
EA001526B1 (ru) * | 1996-09-20 | 2001-04-23 | Мейдзи Сейка Кайся Лтд. | Кристаллическое вещество цефдиторен пивоксил и его получение |
AU4982097A (en) | 1996-10-18 | 1998-05-15 | Board Of Regents, The University Of Texas System | Anti-erbb2 antibodies |
DE19782096T1 (de) | 1996-11-06 | 2000-03-23 | Sequenom Inc | Immobiliserung von Nucleinsäuren in hoher Dichte |
CA2274641A1 (en) | 1996-12-12 | 1998-06-18 | David Richard Corbin | Improved packaging composition |
US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
WO1999006587A2 (en) | 1997-08-01 | 1999-02-11 | Morphosys Ag | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
US20030060612A1 (en) | 1997-10-28 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
DE69839942D1 (de) | 1997-10-29 | 2008-10-09 | Genentech Inc | Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1 |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US6914130B2 (en) | 1998-06-17 | 2005-07-05 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US6747055B1 (en) * | 1998-07-17 | 2004-06-08 | The United States Of America As Represented By The Department Of Health And Human Services | Water-soluble drugs and methods for their production |
WO2000020579A1 (en) | 1998-10-02 | 2000-04-13 | Mcmaster University | Spliced form of erbb-2/neu oncogene |
PT1157041E (pt) | 1999-03-01 | 2005-10-31 | Genentech Inc | Anticorpos para terapia e diagnostico de cancro |
DK2266537T3 (en) | 1999-04-01 | 2014-12-15 | Talon Therapeutics Inc | Compositions for treating cancer |
US6416758B1 (en) | 1999-04-28 | 2002-07-09 | Board Of Regents, The University Of Texax System | Antibody conjugate kits for selectively inhibiting VEGF |
WO2000067796A1 (en) | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
AU4809299A (en) | 1999-05-12 | 2000-12-05 | Array Ab | Direct printing device with cleaning unit |
SI1187632T1 (sl) | 1999-05-14 | 2009-04-30 | Genentech Inc | Zdravljenje z anti-ErbB2 protitelesi |
CA2727172A1 (en) | 1999-05-26 | 2001-01-04 | Genentech, Inc. | Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
EP1191944A2 (en) | 1999-06-25 | 2002-04-03 | Genentech, Inc. | METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
KR100754049B1 (ko) | 1999-06-25 | 2007-08-31 | 제넨테크, 인크. | 전립선암을 치료하기 위한 약제 제조에 사용되는 항-ErbB2 항체 및 조성물 |
US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6362342B1 (en) | 1999-06-29 | 2002-03-26 | Lion Bioscience Ag | Triazole compounds and methods of making same |
KR20080075044A (ko) | 1999-07-12 | 2008-08-13 | 제넨테크, 인크. | Cd20에 결합하는 길항제를 사용한 외래 항원에 대한 면역반응 차단 방법 |
US6531131B1 (en) * | 1999-08-10 | 2003-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for Neisseria meningitidis |
US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
EP2111870A1 (en) | 1999-08-27 | 2009-10-28 | Genentech, Inc. | Dosages for treatment of anti-erbB2 antibodies |
US7030231B1 (en) | 1999-09-30 | 2006-04-18 | Catalyst Biosciences, Inc. | Membrane type serine protease 1 (MT-SP1) and uses thereof |
US7303749B1 (en) | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
EP2266607A3 (en) | 1999-10-01 | 2011-04-20 | Immunogen, Inc. | Immunoconjugates for treating cancer |
BE1012928A6 (nl) | 1999-10-07 | 2001-06-05 | Hoeberigs Jean Marie Mathieu | Cilinderoven voor verwarming van frites met hete lucht. |
IL149116A0 (en) | 1999-10-29 | 2002-11-10 | Genentech Inc | Anti-prostate stem cell antigen (psca) antibody compositions and methods of use |
US6824780B1 (en) | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
AU765588C (en) | 1999-11-24 | 2004-12-16 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
BR0108268A (pt) * | 2000-02-11 | 2003-03-05 | Lilly Co Eli | N-acilação seletiva de análogos de glicopeptìdeo a82846 |
PL358187A1 (en) | 2000-02-24 | 2004-08-09 | Genentech, Inc. | Caspase activated prodrugs therapy |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
WO2002013843A2 (en) | 2000-08-17 | 2002-02-21 | University Of British Columbia | Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours |
US6596503B1 (en) | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
JP2004520806A (ja) | 2000-08-24 | 2004-07-15 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
ATE457318T1 (de) | 2000-12-28 | 2010-02-15 | Kyowa Hakko Kirin Co Ltd | Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper |
US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
EP2000148A1 (en) | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of prostate cancer |
US20040235068A1 (en) | 2001-09-05 | 2004-11-25 | Levinson Arthur D. | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
EP1432446B1 (en) * | 2001-09-05 | 2011-04-27 | Genentech, Inc. | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation |
US20080085283A1 (en) | 2001-09-05 | 2008-04-10 | Levinson Arthur D | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
US20030109682A1 (en) * | 2001-09-07 | 2003-06-12 | Daniel Santi | Maytansines and maytansine conjugates |
NZ531674A (en) | 2001-09-18 | 2009-03-31 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
US20050238650A1 (en) | 2002-04-17 | 2005-10-27 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US6716821B2 (en) * | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
NZ533657A (en) | 2002-01-03 | 2008-01-31 | Smithkline Beecham Corp | Methods for the preparation of immunoconjugates, in particular maytansinoids conjugated to a monoclonal antibody |
US7094579B2 (en) | 2002-02-13 | 2006-08-22 | Xoma Technology Ltd. | Eukaryotic signal sequences for prokaryotic expression |
JP2006502110A (ja) | 2002-07-03 | 2006-01-19 | イミュノジェン・インコーポレーテッド | 非放出Muc1およびMuc16に対する抗体、およびその使用 |
ATE499116T1 (de) * | 2002-08-16 | 2011-03-15 | Immunogen Inc | Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln |
JP2006510735A (ja) | 2002-08-19 | 2006-03-30 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
CA2930485C (en) * | 2003-05-14 | 2018-04-10 | Immunogen, Inc. | Maytansinoid-antibody conjugate compositions |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) * | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
WO2005009369A2 (en) | 2003-07-21 | 2005-02-03 | Immunogen, Inc. | A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
US7754441B2 (en) | 2003-11-17 | 2010-07-13 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
JP3991983B2 (ja) | 2003-12-19 | 2007-10-17 | 日産自動車株式会社 | 車両の駆動制御装置 |
JP4658967B2 (ja) | 2003-12-24 | 2011-03-23 | ジェネンテック, インコーポレイテッド | 造血系起源の腫瘍の治療のための組成物と方法 |
WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
CN102973947A (zh) | 2004-06-01 | 2013-03-20 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
US7521541B2 (en) | 2004-09-23 | 2009-04-21 | Genetech Inc. | Cysteine engineered antibodies and conjugates |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
JP5196654B2 (ja) | 2005-06-20 | 2013-05-15 | ジェネンテック, インコーポレイテッド | 腫瘍の診断と治療のための組成物と方法 |
US7195520B1 (en) | 2006-07-18 | 2007-03-27 | Chung-Chuan Huang | Connector for antenna |
KR20210131473A (ko) | 2008-03-18 | 2021-11-02 | 제넨테크, 인크. | 항-her2 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법 |
MY186725A (en) * | 2008-04-30 | 2021-08-13 | Immunogen Inc | Cross-linkers and their uses |
US20110165155A1 (en) | 2009-12-04 | 2011-07-07 | Genentech, Inc. | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 |
CN102971012B (zh) | 2010-03-12 | 2016-05-04 | 伊缪诺金公司 | Cd37结合分子及其免疫缀合物 |
AU2011338383A1 (en) | 2010-12-09 | 2012-06-14 | Genentech, Inc. | Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1 |
-
2004
- 2004-10-08 US US10/960,602 patent/US8088387B2/en active Active
- 2004-10-12 JP JP2006533951A patent/JP2007520450A/ja active Pending
- 2004-10-12 DK DK04793896.4T patent/DK1689846T3/da active
- 2004-10-12 NZ NZ583844A patent/NZ583844A/en unknown
- 2004-10-12 NZ NZ545195A patent/NZ545195A/en unknown
- 2004-10-12 WO PCT/US2004/030917 patent/WO2005037992A2/en active Application Filing
- 2004-10-12 EA EA200600752A patent/EA010508B1/ru active Protection Beyond IP Right Term
- 2004-10-12 BR BRPI0415448A patent/BRPI0415448A8/pt not_active Application Discontinuation
- 2004-10-12 KR KR1020067006874A patent/KR20060130552A/ko not_active Application Discontinuation
- 2004-10-12 EP EP04793896A patent/EP1689846B1/en active Active
- 2004-10-12 PT PT47938964T patent/PT1689846E/pt unknown
- 2004-10-12 CN CN201710333830.XA patent/CN107198778A/zh not_active Withdrawn
- 2004-10-12 EP EP12196827.5A patent/EP2596804A3/en not_active Withdrawn
- 2004-10-12 CN CN201810464381.7A patent/CN108578710B/zh active Active
- 2004-10-12 CA CA2542128A patent/CA2542128C/en active Active
- 2004-10-12 KR KR1020137020144A patent/KR101476082B1/ko active IP Right Grant
- 2004-10-12 KR KR1020127004142A patent/KR101343676B1/ko active IP Right Grant
- 2004-10-12 AU AU2004282491A patent/AU2004282491C1/en active Active
- 2004-10-12 CN CN201310118580XA patent/CN103223174A/zh active Pending
- 2004-10-12 SI SI200432024T patent/SI1689846T1/sl unknown
- 2004-10-12 KR KR1020137023561A patent/KR101573124B1/ko active IP Right Grant
- 2004-10-12 CA CA3139478A patent/CA3139478A1/en active Pending
- 2004-10-12 EP EP12196813.5A patent/EP2596803A3/en active Pending
- 2004-10-12 ES ES04793896T patent/ES2404304T3/es active Active
- 2004-10-12 EP EP12196817.6A patent/EP2612682A3/en not_active Withdrawn
- 2004-10-12 PL PL04793896T patent/PL1689846T3/pl unknown
-
2006
- 2006-02-09 IL IL173625A patent/IL173625A/en active IP Right Grant
- 2006-03-28 EC EC2006006461A patent/ECSP066461A/es unknown
- 2006-04-21 NO NO20061772A patent/NO337458B1/no active Protection Beyond IP Right Term
-
2007
- 2007-10-29 US US11/927,235 patent/US8563509B2/en active Active
- 2007-10-29 US US11/927,251 patent/US7989598B2/en active Active
- 2007-10-29 US US11/927,314 patent/US8198417B2/en active Active
- 2007-10-29 US US11/927,217 patent/US8163888B2/en active Active
-
2008
- 2008-02-27 HK HK18104043.9A patent/HK1244452A1/zh unknown
-
2010
- 2010-08-12 AU AU2010212291A patent/AU2010212291C1/en active Active
-
2011
- 2011-07-04 JP JP2011148625A patent/JP5718745B2/ja active Active
- 2011-07-08 US US13/178,728 patent/US8685920B2/en active Active
- 2011-08-22 IL IL214788A patent/IL214788A0/en active IP Right Grant
-
2012
- 2012-05-11 US US13/469,550 patent/US20120226025A1/en not_active Abandoned
-
2013
- 2013-05-08 CY CY20131100372T patent/CY1113984T1/el unknown
- 2013-05-09 HR HRP20130412TT patent/HRP20130412T1/hr unknown
- 2013-12-13 HU HUS1300075C patent/HUS1300075I1/hu unknown
- 2013-12-16 LU LU92336C patent/LU92336I2/fr unknown
- 2013-12-18 BE BE2013C075C patent/BE2013C075I2/fr unknown
-
2014
- 2014-01-16 CY CY2014002C patent/CY2014002I2/el unknown
- 2014-02-04 US US14/172,360 patent/US20140154804A1/en not_active Abandoned
- 2014-04-07 JP JP2014078553A patent/JP5926759B2/ja active Active
- 2014-10-21 IL IL235253A patent/IL235253B/en active IP Right Grant
-
2016
- 2016-01-26 NO NO2016001C patent/NO2016001I2/no not_active IP Right Cessation
- 2016-02-08 JP JP2016021695A patent/JP2016135786A/ja active Pending
- 2016-07-05 IL IL246605A patent/IL246605A/en active IP Right Grant
-
2017
- 2017-01-23 US US15/413,153 patent/US10844135B2/en active Active
- 2017-06-12 JP JP2017114877A patent/JP2017200934A/ja not_active Withdrawn
-
2018
- 2018-10-02 JP JP2018187555A patent/JP2019011363A/ja active Pending
-
2019
- 2019-03-04 JP JP2019038151A patent/JP2019142864A/ja active Pending
-
2020
- 2020-08-05 JP JP2020132965A patent/JP2020189854A/ja not_active Withdrawn
- 2020-10-07 US US17/064,981 patent/US20210261683A1/en not_active Abandoned
-
2022
- 2022-02-18 JP JP2022023780A patent/JP2022068295A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066461A (es) | Método para activar las poblaciones de célula especificas utilizando conjugados maitansinoides del agente de enlace celular enlazados a través de un enlazador no divisible, dichos conjugados, y métodos para hacer dichos conjugados | |
CR20150350A (es) | Proceso para preparar conjugados de anticuerpo y maytansinoide | |
AR069747A1 (es) | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion | |
EA200702575A1 (ru) | Иммуногенная композиция | |
TR201909909T4 (tr) | Oligosakkarit- protein konjugeleri. | |
WO2004029219A3 (en) | Cell-based rna interference and related methods and compositions | |
PH12015500093A1 (en) | Il-17 binding proteins | |
NO20083891L (no) | Anti-5T4 antistoffer og anvendelser derav | |
ECSP055635A (es) | Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico | |
ATE514755T1 (de) | Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung | |
MY148231A (en) | Leptomycin derivatives | |
BRPI9910394B8 (pt) | molÉculas de ligaÇço especÍfica para cintigrafia e conjugados contendo as mesmas | |
BRPI0611872B8 (pt) | reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica | |
HN2008001104A (es) | Compuestos para anticuerpos de dickpf-1 y70-4 | |
ECSP056149A (es) | Agentes citotóxicos mejorados que comprenden nuevos maitansinoides | |
NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
CY1112414T1 (el) | Υλικα οφθαλμικων και ωτορινολαρυγγολογικων συσκευων | |
WO2005116252A8 (en) | Methods for evaluating ribonucleotide sequences | |
BRPI0518209A (pt) | agentes de ligação especìficos à angiopoietina-2 | |
WO2007087365A3 (en) | Detection of glutathionylated proteins | |
BRPI0611813A2 (pt) | mÉtodo de uso de antagonistas de zonulina para prevenir a perda de ou para regenerar cÉlulas pancreÁticas | |
GT200300046A (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso | |
YU90301A (sh) | Konjugati i postupci za njihovu proizvodnju i njihova upotreba za transport molekula kroz biološke membrane | |
DE60109430D1 (de) | An entzündlichen darmerkrankungen beteiligte gene und deren verwendung | |
ATE304709T1 (de) | Substanzen mit verzweigten linkermolekülen |